---
title: "Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Terms and abbreviations"
description: "Formulary evidence on Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/terms-and-abbreviations"
published: "2026-09-28T12:24:10-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| 3PL | Third-party logistics |
| ADA | Anti-drug antibody |
| AMD | Age-related macular degeneration |
| ATE | Arterial thromboembolic event |
| AUC | Area under the concentration-time curve |
| BCVA | Best corrected visual acuity |
| BLA | Biologics license application |
| BPCIA | Biologics Price Competition and Innovation Act |
| BRVO | Branch retinal vein occlusion |
| CATT | Comparison of Age-related Macular Degeneration Treatments Trials |
| CFR | Code of Federal Regulations |
| CFT | Central foveal thickness |
| CI | Confidence interval |
| Cmax | Maximum plasma concentration |
| CMC | Chemistry, manufacturing, and controls |
| CNV | Choroidal neovascularization |
| CRL | Complete response letter |
| DME | Diabetic macular edema |
| EC | European Commission |
| ETDRS | Early Treatment Diabetic Retinopathy Study |
| EU | European Union |
| FDA | Food and Drug Administration |
| FES-I | Falls Efficacy Scale-International |
| GA | Geographic atrophy |
| HCPCS | Healthcare Common Procedure Coding System |
| ICGA | Indocyanine green angiography |
| ITT | Intention-to-treat |
| MHRA | Medicines and Healthcare products Regulatory Agency |
| nAMD | Neovascular age-related macular degeneration |
| NCT | National Clinical Trial (ClinicalTrials.gov identifier prefix) |
| NI | Non-inferiority |
| OCT | Optical coherence tomography |
| OCTA | Optical coherence tomography angiography |
| ONS-5010 | Development code name for bevacizumab-vikg used prior to FDA approval |
| PCV | Polypoidal choroidal vasculopathy |
| PDT | Photodynamic therapy |
| PDUFA | Prescription Drug User Fee Act |
| PED | Pigment epithelial detachment |
| PFS | Pre-filled syringe |
| PP | Per-protocol |
| PRN | As needed (pro re nata) |
| Q12W | Every 12 weeks |
| Q16W | Every 16 weeks |
| RPE | Retinal pigment epithelium |
| RVO | Retinal vein occlusion |
| SD | Standard deviation |
| SPA | Special Protocol Assessment |
| UK | United Kingdom |
| VEGF | Vascular endothelial growth factor |
| WAC | Wholesale acquisition cost |

## Related pages
- [Lytenava (bevacizumab-vikg): Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration.md)
- [Lytenava (bevacizumab-vikg): Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/executive-summary.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/clinical-evidence.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/economics.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: References](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/references.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: drug evaluation](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/oregon) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/oregon.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: new drug review](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/review) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/review.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: prevalence by geography](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/prevalence) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/prevalence.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses.md)
